News
We send the latest information from SMC Laboratories.
Can-Fite reports on progress with its Namodenoson NASH program
Can-Fite (Israel) reports on 14 December, 2020, on progress with its Namodenoson NASH program. For detailed information, see the below URL. https://www.cytodyn.com/newsroom/press-releases/detail/489/cytodyn-announces-first-patient-enrolled-in-phase-2-trial
CytoDyn announces first patient enrolled in Phase 2 study for NASH
CytoDyn (USA, KY) announced on 2 December, 2020, the first patient first visit metric was met for the Phase 2 study for NASH. For detailed information, see the below URL. https://www.cytodyn.com/newsroom/press-releases/detail/489/cytodyn-announces-first-patient-enrolled-in-phase-2-trial Leronlimab is a CCR5 agonist.We are looking forward to clinical results.
Inventiva announces FDA has granted Breakthrough Therapy designation to lanifibranor in NASH
Inventiva (France) announced on 12 October, 2020, FDA haas granted Breakthrough Therapy designation to lanifibranor for the treatment of NASH. For detailed information, see the below URL. http://www.globenewswire.com/news-release/2020/10/12/2107044/0/en/Inventiva-receives-FDA-Breakthrough-Therapy-designation-for-lead-drug-candidate-lanifibranor-in-NASH.html Lanifibranor is a PPAR agonist with moderate and well-balanced activity on the three PPAR isoforms (a, g, σ) This compound is also currently undergoing Phase…
Our clients’ presentations at AASLD ~The Liver Meeting Digital Experience~
Our clients presented data on treatment of NASH using STAMTM model at the AASLD ~The Liver Meeting Digital Experience~ (November 13-16). For detailed information, see the below URL. https://aasldpubs.onlinelibrary.wiley.com/toc/15273350/2020/72/S1 Poster #554 Iron loss triggers mitophagy through induction of mitochondrial ferritin Institution: Kawasaki Medical School (Japan) Poster #568 Oxysterol transformation of fatty liver…
Virginia Comonwealth University's publication in Journal of lipid research
SMC announces that Virginia Commonwealth University (Virginia) has published the results of a study using STAMTM mouse model in Journal of lipid research. Title: “Insulin resistance dysregulateds CYP7B1 leading to oxysterol accumulation: a pathway for NAFL to NASH transition” In this paper, they report the involvement of CYP7B1 in the transition from NAFL…
Aldafermin improves fibrosis in patiants with NASH
NGM Biopharmaceuticals, Inc. (USA) presented on August, 2020, the results of the phase 2 trial which met its primary endpoint, achieving a statistically significant reduction in liver fat content, robust fibrosis improvement, and resolution of NASH, with a favorable safety profile. For detailed information, see the below URL. https://ir.ngmbio.com/news-releases/news-release-details/ngm-bio-presents-comprehensive-findings-24-week-phase-2-study It has been reported…
89bio announces positive topline results from its phase 1b/2a trial of BIO89-100 in NASH
89bio (Israel) announced on 14 September, 2020, positive topline results from its Phase 1b/2a trial with BIO89-100 in patients with NASH. BIO89-100 treatment group demonstrated significant reductions in liver fat. For detailed information, see the below URL. https://ir.89bio.com/news-releases/news-release-details/89bio-announces-positive-topline-results-its-phase-1b2a-trial BIO89-100 is a FGF21 analog. Another FGF21 analog, Bristol-Myers Squibb's BMS-986036, is also currently undergoing…
Gilead Sciences, Inc. presented results of the phase 2b ATLAS trial at EASL ~The Digital International Liver Congress™ 2020 ~
Gilead Sciences, Inc. (USA) presented on August, 2020, the results of the phase 2b trial for NASH cirrhosis at EASL ~The Digital International Liver Congress™ 2020 ~. For detailed information, see the below URL. https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Improvement of NASH cirrhosis has been reported by combination of cirofexor (FXR agonist) and firsocostat (ACC inhibitor). Combination…
Galectin Therapeutics announces commencement of patient enrolment of the adaptively-designed Phase 2b/3 trial of Belapectin (GR-MD-02) in NASH cirrhosis
Galectin Therapeutics (USA) announced on June 30, 2020, the commencement of patient enrolment of the adaptively-designed Phase 2b/3 trial of Belapectin (R-MD-02) in NASH cirrhosis. For detailed information, see the below URL. https://investor.galectintherapeutics.com/news-releases/news-release-details/update-galectin-therapeutics-announces-commencement-patient Belapectin is a galectin-3 inhibitor. The compound used the STAMTM mouse model for non-clinical studies, and data showing the improvement…
Terns Pharmaceuticals Inc. announced that initiation of patient dosing in the LIFT study, a phase 2A clinical trial of TERN-101 in development for NASH
Terns Pharmaceuticals Inc. (USA and Shanghai) announced on 23 July, 2020, the initiation of patient dosing in the Phase2A study (LIFT study) of TERN-101 in development for NASH. TERN-101 is FXR agonist. This compound is a non-bile acid FXR agonist unlike Intercept's FXR agonist (OCA), which was recently dropped, and is expected to have…